Bispecific Therapy for Relapsed/Refractory Multiple Myeloma

Learn how to spot myeloma progression, distinguish relapse vs refractory disease, and decide when to treat—especially after lenalidomide maintenance and biochemical relapse.

Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse strategies like BCMA CAR-T and genomic profiling.

Track myeloma treatment shift to quadruplets, MRD-guided goals, and relapse strategies including CAR-T and genomic testing for longer survival.

For early relapsed myeloma, see how patient, disease, and prior therapy guide choices—and why teclistamab plus daratumumab shows standout PFS.

Learn when to treat relapsed myeloma: who can wait, who needs urgent therapy, and why bispecifics plus daratumumab reshape 2026 care.

Learn why MRD negativity drives longer survival in multiple myeloma and when to pair teclistamab with daratumumab after CD38 exposure.

BCMA bispecifics in relapsed myeloma deliver 60–70% responses and year-long PFS, expanding options beyond limited CAR T access.

BCMA bispecifics boost relapsed myeloma responses to 60–70% and extend PFS to 12–18 months, offering durable options beyond CAR-T.

Learn how myeloma experts sequence CAR T and bispecifics, boost MRD-negative rates, and why academic-community teamwork improves outcomes.